Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose-binding lectin
Tóm tắt
To determine whether pediatric PICU patients with mannose-binding lectin (MBL) gene polymorphisms associated with low levels of the functional protein have an increased risk of developing sepsis and SIRS. A prospective, observational cohort study in a 22-bed PICU in a tertiary referral centre. One hundred consecutive admissions to a PICU with at least one organ system failure longer than 12 h. Patients were classified into those with infectious or non-infectious insults as the primary reason for intensive care admission. Patients were followed to determine which developed sepsis or non-infection related SIRS using standard criteria. Of the 100 patients 50 had infectious and 50 had non-infectious insults as the precipitant for admission. 42 patients had variant MBL alleles (determined by MBL-2 gene exon 1 and promoter polymorphisms) and were significantly over-represented amongst the 59 patients that developed SIRS. This effect was not explained by differences in age, sex or ethnicity and was seen in both the infection and non-infection subgroups. In patients with infection, variant MBL alleles were associated with increased systemic response (2/15 with localised infection, 10/19 with sepsis and 12/16 with septic shock). MBL serum levels showed close concordance with the genotype and indicated that MBL levels less than 1000 ng/ml are associated with a greatly increased risk of SIRS.
MBL-2 exon 1 polymorphisms with low serum levels of functional MBL protein are associated with a greatly increased risk of developing SIRS and of progression from infection to sepsis and septic shock in paediatric ICU patients.
Tài liệu tham khảo
Marshall JC (2001) Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 29:S99–S106
Vincent JL, Moreno R, Takala J, Willatts S, de Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710
Crowther MA, Marshall JC (2001) Continuing challenges of sepsis research. JAMA 286:1894–1896
Opal SM, Cohen J (1999) Clinical gram-positive sepsis: does if fundamentally differ from gram-negative bacterial sepsis? Crit Care Med 27:1608–1616
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377
Van den BG, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367
Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G et al (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709
Turner MW (1996) Mannose binding lectin: the pluripotent molecule of the innate immune system. Immunol Today 17:532–540
Kuhlman M, Joiner K, Ezekowitz RA (1989) The human mannose-binding protein functions as an opsonin. J Exp Med 169:1733–1745
Tenner AJ, Robinson SL, Ezekowitz RAB (1995) Mannose-binding protein (MBP) enhances mononuclear phagocyte function via a receptor that contains the 126:000 m(r) component of the C1q receptor. Immunity 3:485–493
Jack DL, Read RC, Tenner AJ, Frosch M, Turner MW, Klein NJ (2001) Mannose-binding lectin regulates the inflammatory response of human professional phagocytes to Neisseria meningitidis serogroup B. J Infect Dis 184:1152–1162
Super M, Thiel S, Lu J, Levinsky RJ, Turner MW (1989) Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet II:1236–1239
Lipscombe RJ, Sumiya M, Summerfield JA, Turner MW (1995) Distinct physicochemical characteristics of human mannose binding protein expressed by individuals of differing genotype. Immunology 85:660–667
Madsen HO, Garred P, Thiel S, Kurtzhals JAL, Lamm LU, Ryder LP, Svejgaard A (1995) Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 155:3013–3020
Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P (1998) Different molecular events result in low protein levels of mannan-binding lectin in populations from Southeast Africa and South America. J Immunol 161:3169–3175
Koch A, Melbye M, Sørensen P, Homøe P, Madsen HO, Mølbak K, Hansen CH, Andersen LH, Hahn GW, Garred P (2001) Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 285:1316–1321
Neth O, Hann I, Turner MW, Klein NJ (2001) Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 358:614–618
Summerfield JA, Sumiya M, Levin M, Turner MW (1997) Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 314:1229–1232
Peterslund NA, Koch C, Jensenius JC, Thiel S (2001) Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 358:637–638
Santos IK, Costa CH, Krieger H, Feitosa MF, Zurakowski D, Fardin B, Gomes RB, Weiner DL, Harn DA, Ezekowitz RA et al (2001) Mannan-binding lectin enhances susceptibility to visceral leishmaniasis. Infect Immun 69:5212–5215
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644–1655
Hayden WR (1993) Sepsis and organ failure definitions and guidelines. Crit Care Med 21:1612–1613
Shann F, Pearson G, Slater A, Wilkinson K (1997) Paediatric index of mortality (PIM): a mortality prediction model for children in intensive care. Intensive Care Med 23:201–207
Leteurtre S, Martinot A, Duhamel A, Gauvin F, Grandbastien B, Nam TV, Proulx F, Lacroix J, Leclerc F (1999) Development of a pediatric multiple organ dysfunction score: use of two strategies. Med Decis Making 19:399–410
Jack D, Bidwell J, Turner M, Wood N (1997) Simultaneous genotyping for all three known structural mutations in the human mannose-binding lectin gene. Hum Mutat 9:41–46
Turner MW, Dinan L, Heatley S, Jack DL, Boettcher B, Lester S, McCluskey J, Roberton DM (2000) Restricted polymorphism of the mannose-binding lectin gene of indigenous Australians. Hum Mol Genet 9:1481–1486
Mead R, Jack D, Pembrey M, Tyfield L, Turner M and the ALSPAC Study Team (1997) Mannose-binding lectin alleles in a prospectively recruited UK population. Lancet 349:1669–1670
Reid CL, Perrey C, Pravica V, Hutchinson IV, Campbell IT (2002) Genetic variation in proinflammatory and anti-inflammatory cytokine production in multiple organ dysfunction syndrome. Crit Care Med 30:2216–2221
Stuber F, Petersen M, Bokelmann F, Schade U (1996) A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 24:381–384
Slutsky AS, Russell J (2002) Genetics of critical illness: methodological issues. Crit Care Med 30:2382–2383
Garred P, Strom J, Quist L, Taaning E, Madsen HO (2003) Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 188:1394–1403
Jordan JE, Montalto MC, Stahl GL (2001) Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 104:1413–1418
Garred P, Richter C, Madsen HO, Mtoni I, Svejgaard A, Shao J (1997) Mannan-binding lectin in the sub-Saharan HIV and tuberculosis epidemics. Scand J Immunol 46:204–208
Brandtzaeg P, Hogasen K, Kierulf P, Mollnes TE (1996) The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J Infect Dis 173:647–655
Garred P, Pressler T, Lanng S, Madsen HO, Moser C, Laursen I, Balstrup F, Koch C, Koch C (2002) Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr Pulmonol 33:201–207